Dr. David Valle Speaks About Evolutionary Medicine

In this video, Dr. David Valle, Professor and Director of the Institute of Genetic Medicine at Johns Hopkins University School of Medicine, discusses the advancement of evolutionary medicine and also speaks about the Johns Hopkins Individualized Medicine Program.

Related Videos

Related Content

Advertisement

February 4th 2025

Addressing Cancer Care Barriers Through Community Outreach and Support

Maggie L. Shaw Oscar B. Lahoud, MD Kasey Bond, MPH

February 4 is World Cancer Day, and in these interviews with our Strategic Alliance Partner, NYU Langone Health, we learn about the importance of forming strong relationships with the communities you are located in and with whom you work to optimize cancer-related outcomes.

February 4th 2025

Politics vs Science: The Future of US Public Health

Maggie L. Shaw Perry N. Halkitis, PhD, MS, MPH

On this episode of Managed Care Cast, we speak with Perry N. Halkitis, PhD, MS, MPH, dean of the Rutgers School of Public Health, on the public health implications of the US withdrawal from the World Health Organization and the role of public health leaders in advocating for science and health.

January 29th 2025

How FcRn Blockade Targets Myasthenia Gravis Autoantibodies

Maggie L. Shaw Katie Abouzahr, MD

In part 2 of our interview with Katie Abouzahr, MD, Johnson & Johnson Innovative Medicine, we discuss the challenge inherent in treating adolescents who have the myasthenia gravis and how nipocalimab works via FcRn blockade to reduce the circulating autoantibodies that drive myasthenia gravis.

January 28th 2025

The Evolving Annual Wellness Visit

Laura Joszt, MA Christopher Wheelock, MD

The annual wellness visit is beneficial for patients, providers, and payers with an emphasis on preventive care for early intervention.

January 28th 2025

Balancing Longevity, Quality, and Cost in Oncology Care

Kyle Munz Kirollos Hanna, PharmD

Kirollos Hanna, PharmD, BCPS, BCOP, FACCC, director of pharmacy at Minnesota Oncology, discusses how the prospect of patient longevity, amidst advancing therapeutics, factors into oncology care.

January 25th 2025

An Argument for Outpatient Bispecific Antibody Delivery: Dr Kirollos Hanna

Kyle Munz Kirollos Hanna, PharmD

Bispecific antibodies have altered the multiple myeloma (MM) treatment landscape, but some practices still lack enough familiarity with these therapeutics to deliver them in outpatient settings.

Related Content

Advertisement

February 4th 2025

Addressing Cancer Care Barriers Through Community Outreach and Support

Maggie L. Shaw Oscar B. Lahoud, MD Kasey Bond, MPH

February 4 is World Cancer Day, and in these interviews with our Strategic Alliance Partner, NYU Langone Health, we learn about the importance of forming strong relationships with the communities you are located in and with whom you work to optimize cancer-related outcomes.

February 4th 2025

Politics vs Science: The Future of US Public Health

Maggie L. Shaw Perry N. Halkitis, PhD, MS, MPH

On this episode of Managed Care Cast, we speak with Perry N. Halkitis, PhD, MS, MPH, dean of the Rutgers School of Public Health, on the public health implications of the US withdrawal from the World Health Organization and the role of public health leaders in advocating for science and health.

January 29th 2025

How FcRn Blockade Targets Myasthenia Gravis Autoantibodies

Maggie L. Shaw Katie Abouzahr, MD

In part 2 of our interview with Katie Abouzahr, MD, Johnson & Johnson Innovative Medicine, we discuss the challenge inherent in treating adolescents who have the myasthenia gravis and how nipocalimab works via FcRn blockade to reduce the circulating autoantibodies that drive myasthenia gravis.

January 28th 2025

The Evolving Annual Wellness Visit

Laura Joszt, MA Christopher Wheelock, MD

The annual wellness visit is beneficial for patients, providers, and payers with an emphasis on preventive care for early intervention.

January 28th 2025

Balancing Longevity, Quality, and Cost in Oncology Care

Kyle Munz Kirollos Hanna, PharmD

Kirollos Hanna, PharmD, BCPS, BCOP, FACCC, director of pharmacy at Minnesota Oncology, discusses how the prospect of patient longevity, amidst advancing therapeutics, factors into oncology care.

January 25th 2025

An Argument for Outpatient Bispecific Antibody Delivery: Dr Kirollos Hanna

Kyle Munz Kirollos Hanna, PharmD

Bispecific antibodies have altered the multiple myeloma (MM) treatment landscape, but some practices still lack enough familiarity with these therapeutics to deliver them in outpatient settings.